Ranbaxy Launches Atorvastatin in Germany

The German subsidiary of Ranbaxy Laboratories Limited (Ranbaxy), Basics GmbH located in Leverkusen, launched Atorvastatin Basics (10/20/40/80 mg), a generic version of the cholesterol lowering drug Sortis, in the German market on March 6, 2012.

Ranbaxy, headquartered in Gurgaon, India, had obtained, pursuant to a settlement agreement with Pfizer, the rights to an early entry of Atorvastatin in the German market. Pfizer's patent for Sortis expires in Germany on May 07, 2012.

Basics' affiliate in Germany, Daiichi Sankyo Deutschland GmbH will assist in the launch. Daiichi Sankyo has a substantial reach amongst Cardiologists and Physicians, in the German market.

Apart from Germany, Daiichi Sankyo and Ranbaxy are working on synergies in other countries, such as India, Romania, Italy and Mexico, among others.